3-Methoxy-4-methylamphetamine (MMA) is a phenethylamine and amphetamine class entactogen and psychedelic medicine. It was first synthesized in 1970 and was discovered in the same decade in Italy as a street drug. MMA was widely overlooked until David E. Nichols re-assayed it as a non-neurotoxic MDMA analogue in 1991, and since the late 2000s (decade) it has subsequently been marketed on the internet as a designer drug.
MMA completely replaces MDMA and MBDB in animal experiments, partly substitutes for LSD, and does not substitute for amphetamine. In addition, it has been shown to powerfully inhibit serotonin reuptake and does not generate serotonergic neurotoxicity in rodents. As a selective serotonin releasing agent (SSRA) and a 5-HT2A receptor agonist, these data tend to confer a profile of MMA.
The symptoms are psychedelic (comparable to DOM) at high doses, such as 120 mg, but can be dysphoric and very long-lasting.